Skip to collection list
Skip to video grid
All Video Abstracts
Utility of DAT in Low-Risk Neonates with ABO or RhD Incompatibility
Routine direct antiglobulin testing adds no predictive value beyond transcutaneous bilirubin monitoring for ABO or RhD incompatible neonates, supporting the discontinuation of universal screening.
Read More
Read Less